173 related articles for article (PubMed ID: 22421905)
1. Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
Sueta D; Nakamura T; Dong YF; Kataoka K; Koibuchi N; Yamamoto E; Toyama K; Yasuda O; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2012 Jun; 25(6):704-10. PubMed ID: 22421905
[TBL] [Abstract][Full Text] [Related]
2. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
[TBL] [Abstract][Full Text] [Related]
3. Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats.
Takai S; Jin D; Shimosato T; Sakonjo H; Miyazaki M
Hypertens Res; 2011 Feb; 34(2):245-52. PubMed ID: 21107329
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.
Kim S; Zhan Y; Izumi Y; Iwao H
Hypertension; 2000 Mar; 35(3):769-74. PubMed ID: 10720593
[TBL] [Abstract][Full Text] [Related]
5. Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats.
Kim-Mitsuyama S; Yamamoto E; Tanaka T; Zhan Y; Izumi Y; Izumiya Y; Ioroi T; Wanibuchi H; Iwao H
Stroke; 2005 May; 36(5):1083-8. PubMed ID: 15817892
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
[TBL] [Abstract][Full Text] [Related]
7. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Daikuhara H; Kikuchi F; Ishida T
Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
9. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
[TBL] [Abstract][Full Text] [Related]
10. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
[TBL] [Abstract][Full Text] [Related]
11. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
[TBL] [Abstract][Full Text] [Related]
12. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of combination of valsartan and amlodipine on salt-induced brain injury in hypertensive rats.
Dong YF; Kataoka K; Tokutomi Y; Nako H; Nakamura T; Toyama K; Sueta D; Koibuchi N; Yamamoto E; Ogawa H; Kim-Mitsuyama S
J Pharmacol Exp Ther; 2011 Nov; 339(2):358-66. PubMed ID: 21807884
[TBL] [Abstract][Full Text] [Related]
14. Effects of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats.
Yao K; Sato H; Sonoda R; Ina Y; Suzuki K; Ohno T
Hypertens Res; 2003 Jul; 26(7):569-76. PubMed ID: 12924625
[TBL] [Abstract][Full Text] [Related]
15. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
Fan YY; Kohno M; Nakano D; Ohsaki H; Kobori H; Suwarni D; Ohashi N; Hitomi H; Asanuma K; Noma T; Tomino Y; Fujita T; Nishiyama A
J Hypertens; 2010 May; 28(5):1034-43. PubMed ID: 20411599
[TBL] [Abstract][Full Text] [Related]
16. Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension.
Zhou MS; Schulman IH; Raij L
Am J Physiol Heart Circ Physiol; 2009 Mar; 296(3):H833-9. PubMed ID: 19151253
[TBL] [Abstract][Full Text] [Related]
17. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
[TBL] [Abstract][Full Text] [Related]
18. Coronary vascular dysfunction promoted by oxidative-nitrative stress in SHRSP.Z-Lepr(fa) /IzmDmcr rats with metabolic syndrome.
Kagota S; Fukushima K; Umetani K; Tada Y; Nejime N; Nakamura K; Mori H; Sugimura K; Kunitomo M; Shinozuka K
Clin Exp Pharmacol Physiol; 2010 Nov; 37(11):1035-43. PubMed ID: 20659132
[TBL] [Abstract][Full Text] [Related]
19. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
London G; Schmieder R; Calvo C; Asmar R
Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
Ueshima K; Oba K; Yasuno S; Fujimoto A; Sato T; Fukiyama K; Azuma J; Ogihara T; Saruta T; Nakao K;
Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
